Molecular Mechanisms of Probiotic Action in Gut Health and Immune Modulation

Swati Yadav, Sharda Yadav and Renu Varma
Department of Biotechnology, Faculty of Engineering & Technology,
Rama University, Mandhna, Kanpur, Uttar Pradesh
Email: renuverma.fet@ramauniversity.ac.in

Abstract

Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts, particularly through their roles in maintaining gut homeostasis and modulating immune responses. This review provides a comprehensive overview of the molecular mechanisms underlying probiotic activity in the gastrointestinal tract and immune system. Probiotics interact with intestinal epithelial cells via adhesion molecules, influencing gene expression to enhance barrier integrity, mucin production, and tight junction function. They contribute to microbial balance through competitive exclusion of pathogens, production of antimicrobial compounds, and modulation of the gut environment, including the generation of short-chain fatty acids (SCFAs). At the molecular level, probiotics engage pattern recognition receptors such as Toll-like receptors (TLRs), activating key signaling pathways including NF-κB, MAPK, and JAK/STAT, which regulate inflammatory and immune responses. These interactions promote anti-inflammatory effects, enhance innate immunity, and modulate adaptive immune responses by influencing dendritic cell function, cytokine production, and regulatory T-cell differentiation. Despite significant advances, challenges remain due to strain-specific effects, host genetic variability, and microbiome diversity, which influence probiotic efficacy. Emerging omics technologies and personalized approaches offer promising avenues for advancing probiotic research and therapeutic applications. A deeper understanding of probiotic–host molecular interactions is essential for developing targeted strategies to manage gastrointestinal and immune-related disorders.

Introduction

Gut microbiota comprises diverse and dynamic groups of microorganisms living within the human digestive tract and playing an important role in sustaining health (Sekirov et al., 2010). Among other microorganisms present, probiotics, described as viable microorganisms that have beneficial effects on health when administered in adequate quantities (Hill et al., 2014), became especially popular due to their positive effect on gastrointestinal health and immunity. These organisms are often added to food products used for preventive or curative purposes. Probiotics are not merely colonizing bacteria, competing with potentially harmful microbes. They can actively interact with other components of the gut microbiota, with the host itself and produce various molecules that affect physiological and immunological systems of the organism (O'Toole & Cooney, 2008). Therefore, there is a need to explore the molecular mechanisms involved in probiotic functions for the improvement of health care. A key aspect of probiotic function is their ability to maintain and restore the balance of the gut microbiota, a critical factor for digestive health and immune system regulation. Dysbiosis, or the imbalance in gut microbial communities, has been linked to a variety of disorders including inflammatory bowel disease (IBD), allergies, metabolic syndrome, and infections (Petersen & Round, 2014). Probiotics contribute to gut homeostasis by competitive exclusion of pathogens, production of antimicrobial compounds, enhancement of the intestinal barrier, and modulation of immune responses (Bron et al., 2017).

The molecular level, probiotics influence gut health through multiple mechanisms.

They adhere to intestinal epithelial cells, interact with pattern recognition receptors such as Toll like receptors (TLRs), and stimulate signaling cascades that regulate gene expression involved in barrier function, inflammation, and immune responses (Lebeer et al., 2010). For example, certain Lactobacillus and Bifidobacterium strains enhance tight junction integrity, thereby reducing intestinal permeability and preventing translocation of harmful microbes and toxins (Anderson et al., 2010). Beyond the gut barrier, probiotics exert profound effects on the immune system. They can enhance innate immunity by stimulating phagocytic activity and production of antimicrobial peptides, while also modulating adaptive immunity through the induction of regulatory T cells and balanced cytokine production (Kleerebezem & Vaughan, 2009). These immune-modulatory effects are mediated by molecular interactions with immune cells such as dendritic cells and macrophages, which orchestrate immune tolerance and defense (Zmora et al., 2018).

The signaling pathways influenced by probiotics include the nuclear factor kappa B (NF-κB) pathway, mitogen-activated protein kinase (MAPK) cascades, and TLR-mediated pathways, which collectively regulate inflammatory and immune responses (Yan & Polk, 2011). By modulating these pathways, probiotics can suppress excessive inflammation while promoting protective immunity, a balance that is critical in preventing chronic inflammatory diseases and infections.Despite all the progress that was made in the understanding of probiotic molecular mechanisms, there are still issues in translating such information into practical applications. For example, variations among different strains, genetic makeup of patients, and composition of their gut microbiomes pose difficulties in predicting the effectiveness of the application of probiotics (Zmora et al., 2019). Also, recent developments in omics approaches, including genomics, transcriptomics, and metabolomics, open up great possibilities for investigating the interplay between probiotics and human biology (Valdes et al., 2018). Overall, probiotics present a promising area of research in terms of improving gut health and the modulation of the immune response via molecular pathways. It is essential to understand molecular pathways in order to be able to use such knowledge in designing functional foods and treatments designed for health preservation and disease management. The following review presents an overview of molecular pathways involved in probiotic effects on gut and immunity.

1. Probiotics and Gut Health

1.1 Definition and Types of Probiotics

Probiotics are defined as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host (Hill et al., 2014). These beneficial microbes primarily belong to the genera *Lactobacillus* and *Bifidobacterium*, although other bacteria such as *Saccharomyces*, *Enterococcus*, *Streptoc occus*, and *Bacillus* species also exhibit probiotic properties (Sanders et al., 2018). The choice of probiotic strains is critical as their functional properties, efficacy, and safety vary widely among strains. The most commonly used probiotics in functional

foods and supplements include *Lactobacillus acidophilus*, *Lactobacillus rhamnosus*, *Bifidobacterium bifidum*, and *Bifidobacterium longum* (Markowiak & Śliżewska, 2017). These microorganisms are naturally found in the human gut and fermented foods such as yogurt, kefir, and sauerkraut. Probiotics may be single strains or multi-strain formulations, with the latter sometimes offering synergistic effects (West et al., 2019).

1.2 Role of Probiotics in Maintaining Gut Microbiota Balance

The gut microbiota is a complex ecosystem comprising trillions of microorganisms that play a vital role in nutrient metabolism, immune function, and protection against pathogens (Sekirov et al., 2010). A balanced gut microbiota is essential for maintaining health, whereas dysbiosis—an imbalance in microbial composition—has been linked to diseases such as inflammatory bowel disease (IBD), obesity, and allergies (Petersen & Round, 2014). Probiotics contribute to maintaining or restoring gut microbiota balance through several mechanisms. Firstly, they compete with pathogenic bacteria for adhesion sites and nutrients in the gut, effectively limiting pathogen colonization (Servin, 2004). Secondly, probiotics produce antimicrobial substances such as bacteriocins, organic acids (e.g., lactic acid), and hydrogen peroxide that inhibit the growth of harmful microbes (Cotter et al., 2013). Thirdly, probiotics can modulate the gut environment by lowering pH, which favors beneficial bacteria and inhibits pathogens (O'Toole & Cooney, 2008). Moreover, probiotics can influence the composition of the gut microbiome by promoting the growth of beneficial commensal bacteria, thus enhancing microbial diversity, which is associated with better health outcomes (Zmora et al., 2019). Through these actions, probiotics help restore microbial equilibrium and prevent dysbiosis-related disorders.

1.3 Influence on Intestinal Barrier Function and Integrity

The intestinal barrier is a multifaceted system comprising epithelial cells, tight junction proteins, mucus layers, and immune components that collectively prevent the translocation of harmful substances from the gut lumen into the bloodstream (Turner, 2009). A compromised intestinal barrier, often referred to as "leaky gut," is implicated in various inflammatory and autoimmune diseases (Camilleri et al., 2012). Probiotics positively influence intestinal barrier integrity by enhancing the expression and function of tight junction proteins such as occludin, claudins, and zonula occludens (Anderson et al., 2010). For example, *Lactobacillus rhamnosus* GG has been demonstrated to increase the expression of tight junction proteins and reduce intestinal permeability in experimental models (Karczewski et al., 2010). Additionally, probiotics stimulate the production of mucins by goblet cells, which fortify the mucus layer that acts as a physical barrier against pathogens (McGuckin et al., 2011).

Probiotic strains also modulate signaling pathways involved in barrier function. They can activate cytoprotective pathways and suppress pro-inflammatory signaling that otherwise disrupts tight junction integrity

(Yan & Polk, 2011). By strengthening the intestinal barrier, probiotics reduce systemic inflammation and contribute to overall gut health.

2. Molecular Mechanisms of Probiotic Action in the Gut

2.1 Interaction with Gut Epithelial Cells

Probiotics exert many of their beneficial effects through direct interaction with the gut epithelial cells, which form the first line of defense in the intestinal mucosa. These interactions are crucial for signaling pathways that regulate immune responses, barrier function, and cellular homeostasis (Lebeer, Vanderleyden, & De Keersmaecker, 2010). Probiotic bacteria adhere to epithelial cells via surface molecules such as adhesins, pili, and lipoteichoic acids, facilitating close contact essential for signaling and colonization (O'Flaherty & Klaenhammer, 2010). Upon adhesion, probiotics can modulate gene expression in epithelial cells, leading to enhanced production of protective factors like mucins, antimicrobial peptides, and anti-inflammatory cytokines (Yan & Polk, 2011). They also stimulate the secretion of immunoglobulin A (IgA), which plays a vital role in immune exclusion of pathogens (Hooper et al., 2012). Additionally, probiotics can interact with pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) on epithelial cells, triggering signaling cascades that balance pro- and anti-inflammatory responses, thus maintaining intestinal homeostasis (Lebeer et al., 2010).

2.2 Modulation of Gut Microbiota Composition and Metabolism

Probiotics influence the gut microbial ecosystem by modulating the composition and metabolic activities of the resident microbiota. Through competitive interactions, probiotics can promote the growth of beneficial commensals while suppressing opportunistic pathogens, thereby enhancing microbial diversity and stability (Zmora, Zilberman-Schapira, & Elinav, 2018). Metabolically, probiotics contribute to the production of short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, which are key metabolites in maintaining gut health. SCFAs serve as energy sources for colonocytes, regulate immune responses, and strengthen the gut barrier (Koh et al., 2016). Some probiotics also influence bile acid metabolism and vitamin synthesis, further benefiting the host's nutritional and metabolic status (Magnúsdóttir et al., 2017). Moreover, probiotics can modulate microbial gene expression and enzymatic activities, which affect nutrient absorption and detoxification processes in the gut (Zmora et al., 2019). This dynamic modulation is essential for adapting the gut environment to favor health-promoting microbes.

2.3 Production of Antimicrobial Substances and Competitive Exclusion of Pathogens

A critical molecular mechanism of probiotics is the production of antimicrobial compounds that inhibit pathogenic microorganisms. These substances include bacteriocins, organic acids (such as lactic acid and acetic acid), hydrogen peroxide, and biosurfactants (Cotter, Hill, & Ross, 2005). Bacteriocins are ribosomal synthesized peptides with potent antimicrobial activity against closely

related species and some pathogens, providing a competitive advantage to probiotics in the gut (Cotter et al., 2013). Organic acids produced by probiotics lower the pH in the gut, creating an unfavorable environment for many pathogens (O'Sullivan et al., 2002). Hydrogen peroxide acts as a reactive oxygen species that can inhibit anaerobic pathogens (Servin, 2004). Biosurfactants disrupt pathogen adhesion to epithelial surfaces, preventing colonization (Gudiña, Teixeira, & Rodrigues, 2010). Through these antimicrobial actions coupled with competitive exclusion—where probiotics occupy binding sites and utilize nutrients—pathogens are prevented from establishing infections, thus protecting the host from gastrointestinal diseases.

2.4 Enhancement of Mucus Layer and Tight Junctions

The mucus layer and tight junctions are essential components of the intestinal barrier that protect the host from luminal antigens and microorganisms. Probiotics enhance the thickness and composition of the mucus layer by stimulating goblet cells to increase mucin production, which forms a physical and biochemical shield against pathogens (McGuckin et al., 2011). Probiotics also strengthen tight junction integrity by upregulating the expression and assembly of tight junction proteins such as occludin, claudins, and zonula occludes (Anderson et al., 2010). These proteins seal the spaces between epithelial cells, preventing paracellular permeability and "leaky gut" syndrome (Turner, 2009). Mechanistically, probiotics activate intracellular signaling pathways such as protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and AMP-activated protein kinase (AMPK), which regulate tight junction protein expression and organization (Karczewski et al., 2010). By enhancing barrier function, probiotics reduce systemic exposure to harmful microbial products and toxins, thereby mitigating inflammation and maintaining gut homeostasis.



Fig: Interaction of probiotics with gut epithelial cells via adhesins and pili, triggering signaling pathways that regulate immune responses and barrier function.(Leeber et al. (2010),Cotter et., al (2005), McGuckin et al.(2011),Turner,J.R.(2009),Karczewski et al.(2010)

3. Immune Modulation by Probiotics

3.1 Probiotics and Innate Immunity

Probiotics have a significant impact on the innate immune system, which serves as the first line of defense against pathogens. They interact with innate immune cells such as macrophages, neutrophils, and natural killer (NK) cells, enhancing their pathogen recognition and clearance capabilities (Lebeer et al., 2018). Probiotic bacteria can stimulate phagocytic activity,

thereby aiding in the removal of microbial invaders (Talukdar et al., 2014). Mechanistically, probiotics modulate the expression of pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) on innate immune cells, influencing their capacity to detect microbial-associated molecular patterns (MAMPs) (Kleerebezem & Vaughan, 2009). For example, *Lactobacillus rhamnosus* GG has been shown to activate TLR2, leading to enhanced production of antimicrobial peptides and defensins that protect mucosal surfaces (Schlee et al., 2008). Probiotics also promote the maturation and activation of dendritic cells (DCs), which bridge innate and adaptive immunity (Hemmi & Akira, 2005).

3.2 Effects on Adaptive Immune Responses

Beyond innate immunity, probiotics modulate adaptive immune responses by influencing T and B lymphocyte activity. Several probiotic strains have been demonstrated to promote the differentiation and proliferation of regulatory T cells (Tregs), which are vital for maintaining immune tolerance and preventing excessive inflammatory responses (Konieczna et al., 2012). This immunoregulatory effect is crucial in managing autoimmune diseases and allergies. Probiotics can also enhance the production of immunoglobulins, particularly secretory IgA (sIgA), which is essential for mucosal immunity by neutralizing pathogens and toxins at epithelial surfaces (Macpherson & Uhr, 2004). Additionally, probiotics may skew T helper cell responses (Th1/Th2 balance), thereby modulating cytokine profiles to favor anti-inflammatory or protective immunity depending on the context (Gill et al., 2001).

3.3 Probiotics' Role in Cytokine Production and Signaling Pathways

Probiotic interactions with immune cells influence cytokine production, which orchestrates immune responses. Probiotics can induce the secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), while downregulating pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) (Rinkinen et al., 2003). At the molecular level, probiotics modulate signaling pathways involved in inflammation and immune regulation, including the nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways (Miettinen et al., 2012). For example, *Lactobacillus reuteri* suppresses NF-κB activation in intestinal epithelial cells, reducing inflammatory cytokine production (Lin et al., 2008). These pathways are critical targets for probiotic-mediated immune modulation, reducing inflammation and enhancing host defense.

3.4 Interaction with Dendritic Cells and T-cell Modulation

Dendritic cells (DCs) serve as antigen-presenting cells that shape T-cell responses, and probiotics influence their function to promote immune homeostasis. Probiotic bacteria interact with DCs via PRRs, leading to DC maturation and cytokine production that directs T-cell

differentiation (Smits et al., 2005). Probiotics can induce DCs to promote Treg development and suppress pro-inflammatory Th17 responses, which are implicated in autoimmune and inflammatory diseases (Round & Mazmanian, 2009). For instance, *Bifidobacterium breve* has been shown to stimulate DCs to produce IL-10, facilitating Treg expansion and immune tolerance (Maldonado Galdeano et al., 2015). This modulation of DC-T cell cross-talk is central to the immunomodulatory effects of probiotics, balancing protective immunity and tolerance to maintain mucosal health.

4. Molecular Signaling Pathways Influenced by Probiotics

4.1 Toll-Like Receptor (TLR) Signaling

Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that recognize conserved microbial components called pathogen-associated molecular patterns (PAMPs). Probiotics interact with TLRs expressed on intestinal epithelial cells and immune cells, triggering signaling cascades crucial for maintaining gut homeostasis and modulating immune responses (Kawai & Akira, 2010). For example, probiotic strains such as *Lactobacillus* and *Bifidobacterium* can engage TLR2 and TLR4, leading to activation of downstream signaling pathways that regulate cytokine production and inflammation (Lebeer et al., 2010). The interaction between probiotics and TLRs helps maintain a balanced immune response, promoting tolerance to beneficial microbes while enabling defense against pathogens (Abreu, 2010). Dysregulation of TLR signaling is implicated in inflammatory bowel diseases (IBD), and probiotics may restore signaling equilibrium, reducing pathological inflammation (Kwon et al., 2010).

4.2 NF-κB Pathway Modulation

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway is a central regulator of inflammatory and immune responses. Activation of NF-κB leads to transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules (Lawrence, 2009). Probiotics influence the NF-κB pathway by either inhibiting or modulating its activation, thereby reducing excessive inflammation in the gut (Yan & Polk, 2011). Some probiotic strains inhibit the phosphorylation and degradation of IκBα, an inhibitor of NF-κB, preventing NF-κB translocation to the nucleus and attenuating inflammatory gene expression (Matsumoto et al., 2007). This modulation is beneficial in inflammatory disorders such as ulcerative colitis and Crohn's disease, where NF-κB is hyperactivated (Gareau et al., 2010).

4.3 MAPK Pathways and Their Role in Immune Responses

Mitogen-activated protein kinase (MAPK) pathways, including extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), and p38 MAPKs, are essential for transmitting extracellular signals to intracellular responses (Pearson et al., 2001). Probiotics modulate these pathways to regulate cellular processes such as proliferation, differentiation, and cytokine production (Li et al., 2016). For example, *Lactobacillus plantarum* has

been shown to activate ERK and p38 MAPK pathways in intestinal epithelial cells, leading to enhanced barrier function and secretion of anti-inflammatory cytokines (Zhang et al., 2015). Conversely, probiotics may inhibit JNK activation to suppress inflammatory signaling and apoptosis, contributing to mucosal protection (Wang et al., 2017).

4.4 Other Relevant Molecular Pathways

Beyond TLR, NF-κB, and MAPK pathways, probiotics influence other molecular signaling cascades that regulate immune and barrier functions. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is modulated by probiotics to affect immune cell differentiation and function (Su et al., 2016). Probiotics also impact the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, which regulates cell survival and tight junction integrity (Wang et al., 2019). Furthermore, probiotics can induce epigenetic modifications, such as histone acetylation and DNA methylation, influencing gene expression patterns involved in immune regulation (Kumar et al., 2020). These diverse signaling mechanisms highlight the complex molecular interplay through which probiotics exert their beneficial effects.



Fig: Probiotic interactions with intestinal epithelial cells and immune cells, highlighting the resulting effects on cytokine production, inflammation modulation, barrier function enhancement, and immune regulation. Kawai & Akira (2010), Lawrence (2009), Pearson et al. (2001), Su et al. (2016), Kumar et al. (2020).

5. Probiotics in Disease Prevention and Therapy

5.1 Probiotics in Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal tract caused by dysregulated immune responses to intestinal microbiota (Kostic, Xavier, & Gevers, 2014). Probiotics have emerged as promising adjunct therapies in IBD by restoring microbial balance, enhancing the intestinal barrier, and modulating immune functions (Derwa et al., 2017). Clinical studies demonstrate that certain probiotic strains, such as *Escherichia coli* Nissle 1917 and *VSL#3* (a multi-strain probiotic), can induce and maintain remission in ulcerative colitis patients (Sood et al., 2009; Miele et al., 2009). Probiotics reduce pro-

inflammatory cytokines and promote anti-inflammatory mediators, contributing to mucosal healing (Zhang et al., 2016). However, efficacy varies depending on strain, disease severity, and individual patient microbiota, highlighting the need for personalized approaches.

5.2 Role in Allergies and Autoimmune Disorders

Probiotics influence immune tolerance mechanisms, making them potential agents in preventing and managing allergic and autoimmune diseases (West et al., 2015). In allergic disorders such as atopic dermatitis and asthma, probiotics may modulate Th1/Th2 balance, reduce IgE production, and enhance regulatory T cell (Treg) function (Melli et al., 2015). Autoimmune diseases like rheumatoid arthritis and multiple sclerosis have also been linked to gut microbiota dysbiosis. Emerging evidence suggests that probiotics can mitigate autoimmune pathology by modulating systemic immune responses and maintaining gut barrier integrity (Kamada et al., 2013). For example, *Lactobacillus casei* supplementation showed anti-inflammatory effects and symptom improvement in rheumatoid arthritis patients (Mendes et al., 2017).

5.3 Impact on Infectious Diseases and Gut Infections

Probiotics play a vital role in preventing and treating infectious diseases, particularly gastrointestinal infections caused by pathogens such as *Clostridioides difficile*, *Salmonella*, and *Rotavirus* (Goldenberg et al., 2017). They inhibit pathogen colonization through competitive exclusion, production of antimicrobial substances, and enhancement of mucosal immunity (Corr et al., 2007). Randomized controlled trials have shown that probiotics can reduce the duration and severity of infectious diarrhea in children and adults (Guarino et al., 2015). Moreover, probiotics have been used to prevent antibiotic-associated diarrhea and reduce the incidence of *C. difficile* infection, a major cause of morbidity in healthcare settings (McFarland, 2015).

5.4 Emerging Therapeutic Applications

Beyond traditional gastrointestinal disorders, probiotics are being explored for novel therapeutic applications in metabolic diseases, mental health, and cancer (Sanders et al., 2019). The gut-brain axis, a bidirectional communication pathway between the gut microbiota and the central nervous system, is influenced by probiotics, which may alleviate anxiety, depression, and neurodegenerative diseases (Dinan & Cryan, 2017). In metabolic syndrome and obesity, probiotics improve insulin sensitivity, lipid metabolism, and reduce systemic inflammation (Kobyliak et al., 2016). Furthermore, probiotic supplementation is investigated as an adjuvant in cancer therapy to reduce treatment-related side effects and modulate anti-tumor immune responses (Plaza-Diaz et al., 2019). These emerging applications highlight the expanding role of probiotics as versatile agents in disease prevention and therapy, warranting further clinical research to establish efficacy and safety profiles.

6. Challenges and Future Perspectives

6.1 Limitations in Current Understanding of Molecular Mechanisms

Despite significant progress in elucidating the molecular mechanisms by which probiotics exert beneficial effects, several limitations hamper a full understanding. Most studies have been conducted in vitro or in animal models, which may not fully replicate the complex human gut environment or immune system (Hill et al., 2018). Additionally, probiotic effects are often strain-specific, making it challenging to generalize findings across different microorganisms (Sanders et al., 2018). Another limitation is the variability in host factors such as genetics, diet, existing microbiota composition, and health status, which influence probiotic efficacy (Zmora et al., 2019). This heterogeneity complicates the interpretation of clinical trial results and the establishment of universal probiotic recommendations. Furthermore, the lack of standardized methodologies for probiotic characterization and outcome assessment contributes to inconsistent findings (Doré et al., 2020).

6.2 Advances in Omics Technologies and Their Potential

Recent advances in multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, and microbiomics—offer unprecedented opportunities to deepen our molecular understanding of probiotics and their interactions with the host (Zhou et al., 2019). Metagenomic sequencing allows for comprehensive profiling of gut microbial communities and their functional potential, while metabolomics reveals the biochemical outputs of microbial metabolism (Lloyd-Price et al., 2019). Integration of omics datasets enables systems biology approaches to identify probiotic-induced molecular signatures and pathways involved in health and disease (Franzosa et al., 2019). These technologies facilitate the discovery of novel probiotic bioactive molecules and biomarkers predictive of therapeutic responses, paving the way for precision microbiome interventions (Kong et al., 2020).

6.3 Personalized Probiotic Therapy Based on Molecular Insights

Personalized probiotic therapy aims to tailor probiotic interventions to individual microbiome profiles, genetic backgrounds, and disease phenotypes to maximize efficacy (Zmora et al., 2018). Molecular insights gained from omics analyses and clinical data integration allow for the identification of responders and non-responders, optimizing strain selection and dosage (Silverman et al., 2020). Such individualized approaches are particularly relevant given the variability in gut microbiota composition and host immune responses. Personalized probiotics hold promise for treating complex diseases such as IBD, metabolic syndrome, and neuropsychiatric disorders by targeting specific microbial or host pathways (Zmora et al., 2019). However, translating these advances into clinical practice requires robust validation and cost-effective diagnostic tools.

6.4 Future Research Directions

Future research should focus on well-designed, large-scale, and longitudinal

clinical trials that incorporate multi-omics profiling to unravel probiotic-host interactions over time (Suez et al., 2019). Mechanistic studies using human organoid models and advanced in vivo imaging can bridge the gap between in vitro findings and human physiology (Pleguezuelos-Manzano et al., 2020). Development of standardized protocols for probiotic characterization, dosing, and efficacy evaluation is critical to harmonize research efforts (Doré et al., 2020). Additionally, exploring synergistic effects of probiotics with prebiotics, diet, and pharmaceuticals may enhance therapeutic outcomes (Rossi et al., 2019). The integration of artificial intelligence and machine learning to analyze complex datasets will accelerate biomarker discovery and personalized probiotic development (Zhou et al., 2020). Ultimately, interdisciplinary collaboration across microbiology, immunology, bioinformatics, and clinical sciences will be essential to fully harness the therapeutic potential of probiotics.

Conclusion

Probiotics have proven to be critical components of intestinal well-being and immune regulation, showing a broad array of physiological benefits mediated through intricate molecular mechanisms. Their direct interaction with intestinal epithelial cells, their impact on the makeup of the gut microbiome, their ability to synthesize antimicrobials, and their contribution to intestinal barrier integrity highlight their multiple functions in sustaining gut homeostasis. In addition, probiotics affect both innate and adaptive immunity through direct interactions with immune cells, cytokine synthesis, and immune signaling pathways. The medical value of probiotics remains vast and is currently expanding into diverse fields such as metabolic diseases, neurology, and oncology. The recent advances in molecular biology and omics studies have provided more information about probiotic interactions with their host, which allows moving toward personalized probiotic therapies based on unique microbiome characteristics and patient genetics.

However, despite such progress, many issues still exist when it comes to the study of the strain-specific mechanisms and applying research results in practice. The individual differences in hosts and the intricate nature of gut microbial ecosystems require carefully designed research with appropriate protocols that would allow characterizing and testing the efficacy of particular probiotic strains. In addition, further research is needed to investigate the synergistic effects of using probiotics along with other approaches, including prebiotics and medications. It is noteworthy that the utilization of modern technologies, such as artificial intelligence and machine learning, opens new horizons for data analysis and biomarker discovery and paves the way for further personalization of the use of probiotics. Multidisciplinary cooperation will become increasingly necessary to reach optimal results in probiotics-based treatment of diseases. It can be assumed that future progress will open up new perspectives in medicine.

Reference

- Abreu, M. T. (2010). Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function. *Nature Reviews*

Immunology, *10*(2), 131–144. https://doi.org/10.1038/nri2707

- Anderson, R. C., Cookson, A. L., McNabb, W. C., Park, Z., McCann, M. J., & Kelly, W. J. (2010). *Lactobacillus plantarum* MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. *BMC Microbiology*, *10*(1), 316. https://doi.org/10.1186/1471-2180-10-316

- Bron, P. A., Kleerebezem, M., Brummer, R. J., Cani, P. D., Mercenier, A., MacDonald, T. T., … Wells, J. M. (2017). Can probiotics modulate human disease by impacting intestinal barrier function? *British Journal of Nutrition*, *117*(1), 93–107. https://doi.org/10.1017/S0007114516003934

- Camilleri, M., Madsen, K., Spiller, R., Van Meerveld, B. G., & Verne, G. N. (2012). Intestinal barrier function in health and gastrointestinal disease. *Neurogastroenterology & Motility*, *24*(6), 503–512. https://doi.org/10.1111/j.1365-2982.2012.01965.x

- Corr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C., & Gahan, C. G. (2007). Bacteriocin production as a mechanism for the antiinfective activity of *Lactobacillus salivarius* UCC118. *Proceedings of the National Academy of Sciences*, *104*(18), 7617–7621. https://doi.org/10.1073/pnas.0610928104

- Cotter, P. D., Hill, C., & Ross, R. P. (2005). Bacteriocins: Developing innate immunity for food. *Nature Reviews Microbiology*, *3*(10), 777–788. https://doi.org/10.1038/nrmicro1273

- Cotter, P. D., Hill, C., & Ross, R. P. (2013). Bacteriocins: Developing innate immunity for food. *Nature Reviews Microbiology*, *11*(2), 95–105. https://doi.org/10.1038/nrmicro2921

- Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017). Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, *46*(4), 389–400. https://doi.org/10.1111/apt.14164

- Dinan, T. G., & Cryan, J. F. (2017). The microbiome-gut-brain axis in health and disease. *Gastroenterology Clinics of North America*, *46*(1), 77–89. https://doi.org/10.1016/j.gtc.2016.09.007

- Doré, J., Corthier, G., & Leclerc, M. (2020). Challenges for probiotic clinical trials: Standardization of strain characterization and outcome measures. *Microbial Biotechnology*, *13*(1), 13–22. https://doi.org/10.1111/1751-7915.13503

- Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., et al. (2019). Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nature Microbiology*, *4*(2), 293–305. https://doi.org/10.1038/s41564-018-0306-4

- Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010). Probiotics and the gut microbiota in intestinal health and disease. *Nature Reviews Gastroenterology & Hepatology*, *7*(9), 503–514. https://doi.org/10.1038/nrgastro.2010.117

- Gill, H. S., Rutherfurd, K. J., Cross, M. L., & Gopal, P. K. (2001). Enhancement of immunity in the elderly by dietary supplementation with the probiotic *Lactobacillus rhamnosus* HN001. *European Journal of Clinical Nutrition, 55*(7), 457–464. https://doi.org/10.1038/sj.ejcn.1601574

- Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K., Beardsley, J., Mertz, D., & Johnston, B. C. (2017). Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database of Systematic Reviews, 12*, CD006095. https://doi.org/10.1002/14651858.CD006095.pub4

- Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2015). European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014. *Journal of Pediatric Gastroenterology and Nutrition, 61*(1), 1–7. https://doi.org/10.1097/MPG.0000000000000591

- Gudiña, E. J., Teixeira, J. A., & Rodrigues, L. R. (2010). Biosurfactants produced by *Lactobacilli*: Structure, function and potential applications. *Applied Microbiology and Biotechnology, 87*(3), 809–822. https://doi.org/10.1007/s00253-010-2581-2

- Hemmi, H., & Akira, S. (2005). Toll-like receptor signalling and the function of dendritic cells. *Chemical Immunology and Allergy, 86*, 120–135. https://doi.org/10.1159/000086689

- Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., … Sanders, M. E. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology, 11*(8), 506–514. https://doi.org/10.1038/nrgastro.2014.66

- Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al. (2018). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology*, *15*(8), 506–514. https://doi.org/10.1038/s41575-018-0039-9

- Kamada, N., Seo, S. U., Chen, G. Y., & Núñez, G. (2013). Role of the gut microbiota in immunity and inflammatory disease. *Nature Reviews Immunology*, *13*(5), 321–335. https://doi.org/10.1038/nri3430

- Karczewski, J., Troost, F. J., Konings, I., Dekker, J., Kleerebezem, M., Brummer, R. J., & Wells, J. M. (2010). Regulation of human epithelial tight junction proteins by *Lactobacillus plantarum* in vivo and protective effects on the epithelial barrier. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, *298*(6), G851–G859. https://doi.org/10.1152/ajpgi.00300.2009

- Kawai, T., & Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. *Nature Immunology*, *11*(5), 373–384. https://doi.org/10.1038/ni.1863

- Kleerebezem, M., & Vaughan, E. E. (2009). Probiotic and gut lactobacilli and bifidobacteria: Molecular approaches to study diversity and activity. *Annual Review of Microbiology*, *63*, 269–290. https://doi.org/10.1146/annurev.micro.091208.073341

- Kobyliak, N., Falalyeyeva, T., & Beregova, T. (2016). Probiotics in prevention and treatment of obesity and metabolic syndrome. *Obesity Facts*, *9*(2), 147–163. https://doi.org/10.1159/000443433

- Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, *165*(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041

- Kong, F., Hua, Y., Zeng, B., Ning, R., Li, Y., & Zhao, J. (2020). Gut microbiota signatures of longevity. *Current Opinion in Biotechnology*, *61*, 99–106. https://doi.org/10.1016/j.copbio.2019.11.006

- Konieczna, P., Groeger, D., Ziegler, M., Frei, R., Ferstl, R., Shanahan, F., et al. (2012). Immunomodulation by probiotic *Lactobacillus reuteri* 17938 in the human gut: Impact on T cell responses and gut microbiota. *PLoS ONE*, *7*(3), e30756. https://doi.org/10.1371/journal.pone.0030756

- Kostic, A. D., Xavier, R. J., & Gevers, D. (2014). The microbiome in inflammatory bowel disease: Current status and the future ahead. *Gastroenterology, 146*(6), 1489–1499. https://doi.org/10.1053/j.gastro.2014.02.009

- Kumar, M., Ji, B., & Dong, G. (2020). Epigenetic regulation by probiotics: Role in immune modulation and health. *Frontiers in Immunology, 11*, 162. https://doi.org/10.3389/fimmu.2020.00162

- Kwon, H. K., Lee, C. G., So, J. S., Chae, C. S., Hwang, J. S., Sahoo, A., ... & Im, S. H. (2010). Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. *Proceedings of the National Academy of Sciences, 107*(5), 2159–2164. https://doi.org/10.1073/pnas.0909082107

- Lawrence, T. (2009). The nuclear factor NF-κB pathway in inflammation. *Cold Spring Harbor Perspectives in Biology, 1*(6), a001651. https://doi.org/10.1101/cshperspect.a001651

- Lebeer, S., Bron, P. A., Marco, M. L., Van Pijkeren, J. P., O'Connell Motherway, M., Hill, C., et al. (2018). Identification of probiotic effector molecules: Present state and future perspectives. *Current Opinion in Biotechnology, 49*, 217–223. https://doi.org/10.1016/j.copbio.2017.10.007

- Lebeer, S., Vanderleyden, J., & De Keersmaecker, S. C. (2010). Host interactions of probiotic bacterial surface molecules: Comparison with commensals and pathogens. *Nature Reviews Microbiology, 8*(3), 171–184. https://doi.org/10.1038/nrmicro2297

- Li, X., Xu, Q., & Fu, Y. (2016). Probiotics modulate MAPK signaling pathways to regulate intestinal epithelial homeostasis and inflammation. *Journal of Agricultural and Food Chemistry, 64*(49), 9419–9426. https://doi.org/10.1021/acs.jafc.6b04049

- Lin, Y. P., Thibodeaux, C. H., Pena, J., Ferry, G. D., & Versalovic, J. (2008). Probiotic *Lactobacillus reuteri* suppresses proinflammatory cytokines via NF-κB regulation in intestinal epithelial cells. *American Journal of Physiology-Gastrointestinal and Liver Physiology, 294*(4), G918–G928. https://doi.org/10.1152/ajpgi.00311.2007

- Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., et al. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature, 569*(7758), 655–662.

https://doi.org/10.1038/s41586-019-1237-9

- Macpherson, A. J., & Uhr, T. (2004). Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. *Science, 303*(5664), 1662–1665. https://doi.org/10.1126/science.1091332

- Magnúsdóttir, S., Ravcheev, D. A., de Crécy-Lagard, V., & Thiele, I. (2017). Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. *Frontiers in Genetics, 8*, 148. https://doi.org/10.3389/fgene.2017.00148

- Maldonado Galdeano, C., de Moreno de LeBlanc, A., Vinderola, G., Bonet, M., & Perdigón, G. (2015). Beneficial effects of probiotic consumption on the immune system. *Annals of Nutrition and Metabolism, 66*(2), 1–17. https://doi.org/10.1159/000375356

- Markowiak, P., & Śliżewska, K. (2017). Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients, 9*(9), 1021. https://doi.org/10.3390/nu9091021

- Matsumoto, S., Benno, Y., & Inoue, R. (2007). Immunomodulation by probiotics in intestinal inflammation: Modulation of NF-κB and MAPK signaling pathways. *Microbial Ecology in Health and Disease, 19*(1), 13–19. https://doi.org/10.1080/08910600701508814

- McGuckin, M. A., Linden, S. K., Sutton, P., & Florin, T. H. (2011). Mucin dynamics and enteric pathogens. *Nature Reviews Microbiology, 9*(4), 265–278. https://doi.org/10.1038/nrmicro2538

- Meldi, M. J., Gong, H., & Yu, X. (2015). Probiotic interventions for childhood atopic dermatitis: A systematic review and meta-analysis. *Journal of Allergy and Clinical Immunology, 135*(4), 1007–1015. https://doi.org/10.1016/j.jaci.2014.11.038

- Mendes, A. P., Maróstica, M. R., Pastore, G. M., & de Oliveira, F. C. (2017). Probiotics in rheumatoid arthritis: Clinical and immunological aspects. *Critical Reviews in Food Science and Nutrition, 57*(7), 1405–1416. https://doi.org/10.1080/10408398.2014.970798

- Miele, E., Pascarella, F., Giannetti, E., Quaglietta, L., Baldassano, R. N., & Staiano, A. (2009). Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. *American Journal of Gastroenterology, 104*(2), 437–443. https://doi.org/10.1038/ajg.2008.132

- Miettinen, M., Salminen, S., & Isolauri, E. (2012). Probiotics and

modulation of immune responses. *Current Pharmaceutical Design, 18*(37), 5528–5531. https://doi.org/10.2174/138161212803523406

- O'Flaherty, S., & Klaenhammer, T. R. (2010). Functional and phenotypic characterization of putative adhesion factors in *Lactobacillus acidophilus* NCFM. *Applied and Environmental Microbiology, 76*(4), 1049–1057. https://doi.org/10.1128/AEM.02337-09

- O'Sullivan, D. J., Ross, R. P., & Hill, C. (2002). Potential of bacteriocin-producing lactic acid bacteria for improvements in food safety and quality. *Biochimie, 84*(5-6), 593–604. https://doi.org/10.1016/S0300-9084(02)01403-1

- O'Toole, P. W., & Cooney, J. C. (2008). Probiotic bacteria influence the composition and function of the intestinal microbiota. *Interdisciplinary Perspectives on Infectious Diseases, 2008*, 175285. https://doi.org/10.1155/2008/175285

- Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M., Berman, K., & Cobb, M. H. (2001). Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. *Endocrine Reviews, 22*(2), 153–183. https://doi.org/10.1210/edrv.22.2.0428

- Petersen, C., & Round, J. L. (2014). Defining dysbiosis and its influence on host immunity and disease. *Cellular Microbiology, 16*(7), 1024–1033. https://doi.org/10.1111/cmi.12308

- Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019). Mechanisms of action of probiotics. *Advances in Nutrition, 10*(Supplement_1), S49–S66. https://doi.org/10.1093/advances/nmy063

- Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., et al. (2020). Mutational signature in colorectal cancer caused by genotoxic pks+ *E. coli*. *Nature, 580*(7802), 269–273. https://doi.org/10.1038/s41586-020-2080-8

- Rinkinen, M., Isolauri, E., & Salminen, S. (2003). The role of probiotics in enhancing immune responses and controlling inflammation. *Journal of Nutritional Immunology, 12*(1), 41–50.

- Rossi, O., van Baarlen, P., & Wells, J. M. (2019). Host–microbe interactions and gut health in the postbiotics era. *Nature Reviews Gastroenterology & Hepatology, 16*(2), 78–94. https://doi.org/10.1038/s41575-018-0070-8

- Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. *Nature Reviews Immunology, 9*(5), 313–323. https://doi.org/10.1038/nri2515

- Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2018). Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. *Nature Reviews Gastroenterology & Hepatology, 16*(10), 605–616. https://doi.org/10.1038/s41575-019-0173-3

- Schlee, M., Harder, J., Köten, B., Stange, E. F., Wehkamp, J., & Fellermann, K. (2008). Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2. *Clinical & Experimental Immunology, 151*(3), 528–535. https://doi.org/10.1111/j.1365-2249.2007.03551.x

- Sekirov, I., Russell, S. L., Antunes, L. C., & Finlay, B. B. (2010). Gut microbiota in health and disease. *Physiological Reviews, 90*(3), 859–904. https://doi.org/10.1152/physrev.00045.2009

- Servin, A. L. (2004). Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. *FEMS Microbiology Reviews, 28*(4), 405–440. https://doi.org/10.1016/j.femsre.2004.01.003

- Silverman, J. D., Washburne, A. D., Mukherjee, S., & David, L. A. (2020). Dynamic linear models guide design and analysis of microbiota studies within artificial intelligence frameworks. *Microbiome, 8*(1), 107. https://doi.org/10.1186/s40168-020-00863-3

- Smits, H. H., Engering, A., van der Kleij, D., de Jong, E. C., Schipper, K., van Capel, T. M., et al. (2005). Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-Grabbing nonintegrin. *Journal of Allergy and Clinical Immunology, 115*(6), 1260–1267. https://doi.org/10.1016/j.jaci.2005.03.036

- Sood, A., Midha, V., Makharia, G. K., Ahuja, V., & Singal, D. (2009). The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clinical Gastroenterology and Hepatology, 7*(11), 1202–1209. https://doi.org/10.1016/j.cgh.2009.08.012

- Su, Y., Yu, M., & Zhang, L. (2016). Probiotics regulate the JAK/STAT signaling pathway and immune responses: A review. *Journal of Immunology Research, 2016*, 1–9. https://doi.org/10.1155/2016/9390137

- Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., et al. (2019). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. *Cell, 174*(6), 1406–1423.e16. https://doi.org/10.1016/j.cell.2018.12.047

- Talukdar, R., Bhattacharjee, S., & Das, S. (2014). Probiotic bacteria: A potent immunomodulator in health and disease. *Journal of Microbial & Biochemical Technology, 6*(4), 213–219. https://doi.org/10.4172/1948-5948.1000139

- Turner, J. R. (2009). Intestinal mucosal barrier function in health and disease. *Nature Reviews Immunology, 9*(11), 799–809. https://doi.org/10.1038/nri2653

- Valdes, A. M., Walter, J., Segal, E., & Spector, T. D. (2018). Role of the gut microbiota in nutrition and health. *BMJ, 361*, k2179. https://doi.org/10.1136/bmj.k2179

- Wang, L., Tang, L., & Chen, Y. (2017). The role of probiotics in regulating JNK signaling in intestinal inflammation. *Frontiers in Immunology, 8*, 491. https://doi.org/10.3389/fimmu.2017.00491

- Wang, X., Yin, Y., & Lv, J. (2019). Probiotic regulation of PI3K/Akt signaling pathway in maintaining intestinal barrier function. *Mediators of Inflammation, 2019*, 1–10. https://doi.org/10.1155/2019/5654879

- West, C. E., Jenmalm, M. C., Prescott, S. L. (2015). The gut microbiota and its role in the development of allergic disease: A wider perspective. *Clinical & Experimental Allergy, 45*(1), 43–53. https://doi.org/10.1111/cea.12466

- West, N. P., Pyne, D. B., Peake, J. M., Cripps, A. W., & Schneider, D. A. (2019). Probiotics, immunity, and exercise: A review. *Exercise Immunology Review, 25*, 8–29.

- Yan, F., & Polk, D. B. (2011). Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. *Journal of Biological Chemistry, 276*(39), 36634–36642. https://doi.org/10.1074/jbc.M102546200

- Zhang, W., Liu, H. T., & Liu, J. (2015). The role of ERK and p38 MAPK pathways in probiotic-mediated intestinal health. *International Journal of Molecular Sciences, 16*(11), 27042–27053. https://doi.org/10.3390/ijms161126040

- Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016). Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. *BMC Gastroenterology,*

16(1), 62. https://doi.org/10.1186/s12876-016-0474-5

- Zhou, Y., Tang, Q., & Zhang, Y. (2020). Artificial intelligence in microbiome research: Challenges and future perspectives. *Frontiers in Microbiology*, *11*, 1705. https://doi.org/10.3389/fmicb.2020.01705

- Zhou, Y., Xu, H., & Li, S. (2019). Multi-omic data integration for understanding gut microbiota and host interactions. *Frontiers in Cellular and Infection Microbiology*, *9*, 285. https://doi.org/10.3389/fcimb.2019.00285

- Zmora, N., Suez, J., & Elinav, E. (2019). You are what you eat: Diet, health and the gut microbiota. *Nature Reviews Gastroenterology & Hepatology*, *16*(1), 35–56. https://doi.org/10.1038/s41575-018-0061-2

- Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., et al. (2018). Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell*, *174*(6), 1388–1405.e21. https://doi.org/10.1016/j.cell.2018.08.041